Alnylam Pharmace. buy daimler1
Summary
This prediction ended on 02.04.23 with a price of €186.60. With a performance of 2.35%, the BUY prediction by daimler1 for Alnylam Pharmace. closed with a slight gain. daimler1 has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | 0.550% | 0.550% | 23.453% |
iShares Core DAX® | 0.786% | 1.251% | 11.561% |
iShares Nasdaq 100 | 1.855% | -2.687% | 25.316% |
iShares Nikkei 225® | 3.947% | 2.199% | 11.527% |
iShares S&P 500 | 1.787% | 0.151% | 23.699% |
Comments by daimler1 for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.